廣生堂(300436.SZ):非酒精性脂肪肝病及肝纖維化可逆轉新藥GST-HG151專項課題被正式列入2019年國家重大新藥創制科技重大專項
格隆匯12月23日丨廣生堂(300436.SZ)公佈,公司於近日收到國家衞生健康醫藥衞生科技發展研究中心下發的《關於重大新藥創制科技重大專項2019年度實施計劃立項課題的通知》(衞科專項函[2019]764號),公司專項課題“抗肝纖維化藥物GST-HG151的臨牀前研究及I期臨牀試驗研究”(課題編號2019ZX09201001-003-006)已被列入重大新藥創制科技重大專項2019年度實施計劃立項課題子課題。
公司IPO首發後矢志不移地向創新藥企業轉型,開展了多個創新藥物的研發。此次公司專項課題成功被列入國家重大新藥創制科技重大專項立項課題子課題,是對非酒精性脂肪肝病及肝纖維化可逆轉全球創新藥GST-HG151的高度認可,有助於加快該創新藥研發項目的開發進程,提升公司自主創新能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.